NovoCure (NVCR) Competitors

NovoCure (NASDAQ:NVCR) and Stevanato Group (NYSE:STVN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.

Does the media refer more to NVCR or STVN?

In the previous week, Stevanato Group had 2 more articles in the media than NovoCure. MarketBeat recorded 9 mentions for Stevanato Group and 7 mentions for NovoCure. Stevanato Group's average media sentiment score of 1.27 beat NovoCure's score of 0.92 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in NVCR or STVN?

NovoCure received 447 more outperform votes than Stevanato Group when rated by MarketBeat users. Likewise, 63.52% of users gave NovoCure an outperform vote while only 62.50% of users gave Stevanato Group an outperform vote.

Company	Underperform	Outperform
NovoCure	Outperform Votes 477 63.52%	Underperform Votes 274 36.48%
Stevanato Group	Outperform Votes 30 62.50%	Underperform Votes 18 37.50%

Which has better earnings and valuation, NVCR or STVN?

Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$605.22M	3.37	-$207.04M	-$1.56	-11.91
Stevanato Group	$1.10B	5.76	$157.62M	$0.48	43.73

Which has more risk & volatility, NVCR or STVN?

NovoCure has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Do insiders & institutionals believe in NVCR or STVN?

84.6% of NovoCure shares are held by institutional investors. 6.3% of NovoCure shares are held by insiders. Comparatively, 0.7% of Stevanato Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Is NVCR or STVN more profitable?

Stevanato Group has a net margin of 10.47% compared to NovoCure's net margin of -25.93%. Stevanato Group's return on equity of 9.86% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.93%	-41.48%	-12.74%
Stevanato Group	10.47%	9.86%	5.79%

Do analysts prefer NVCR or STVN?

NovoCure currently has a consensus price target of $35.80, indicating a potential upside of 92.65%. Given NovoCure's stronger consensus rating and higher probable upside, equities research analysts clearly believe NovoCure is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Stevanato Group beats NovoCure on 11 of the 18 factors compared between the two stocks.